- NLG919
-
- $5.00 / 5KG
-
2019-09-04
- CAS:1402836-58-1
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 1ton
|
| Product Name: | NLG919 | | Synonyms: | NLG919;1-CYCLOHEXYL-2-(5H-IMIDAZO[5,1-A]ISOINDOL-5-YL)ETHANOL;5H-Imidazo[5,1-a]isoindole-5-ethanol, α-cyclohexyl-;1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol NLG919;NLG919 1-CYCLOHEXYL-2-(5H-IMIDAZO[5,1-A]ISOINDOL-5-YL)ETHANOL;alpha-Cyclohexyl-5H-imidazo[5,1-a]isoindole-5-ethanol;NLG919, >=98%;NLG919;NLG-919 | | CAS: | 1402836-58-1 | | MF: | C18H22N2O | | MW: | 282.38 | | EINECS: | 1592732-453-0 | | Product Categories: | Inhibitor;Inhibitors | | Mol File: | 1402836-58-1.mol |  |
| | NLG919 Chemical Properties |
| Melting point | 143 - 146°C | | Boiling point | 524.6±33.0 °C(Predicted) | | density | 1.27±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in DMSO (up to 15 mg/ml) | | pka | 14.85±0.20(Predicted) | | form | solid | | color | White | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| | NLG919 Usage And Synthesis |
| Description | (±)-NLG-919 is an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor (Ki = 7 nM; EC50 = 75 nM). (±)-NLG-919 inhibits IDO-induced T cell suppression and restores T cell response during allogenic mixed lymphocyte reactions in vitro (ED50s = 80 and 120 nM, respectively). In vivo, (±)-NLG-919 induces a 95% reduction in tumor volume when administered in conjunction with a pmel-1 T cell vaccine. Formulations containing (±)-NLG-919 are under investigation in clinical trials for treatment of glioblastoma, melanoma, pancreatic, and breast cancers. | | Uses | NLG919 is a potent indoleamine-2,3-dioxygenase (IDO) pathway inhibitor and is suitable for the treatment of immunosuppression associated with cancer. | | target | IDO pathway | | References | 1) Mautino?et al.?(2013),?NLG919, a novel indolamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy;?Cancer Res.?73?issue 8 supplement?491
2) Li?et al.?(2014),?The indolamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma;?J. Immunother. Cancer?2?21
3) Meng?et al.?(2017),?Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model;?Int. J. Immunopathol. Pharmacol.?30?215 |
| | NLG919 Preparation Products And Raw materials |
|